Insider Trading Alert - CPT, PTCT And LNKD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Sept. 16, 2014, 80 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.26 to $11,203,447.50.

Highlighted Stocks Traded by Insiders:

Camden Property (CPT) - FREE Research Report

Hefner Stephen R., who is SVP - Construction at Camden Property, sold 4,134 shares at $69.90 on Sept. 16, 2014. Following this transaction, the SVP - Construction owned 43,942 shares meaning that the stake was reduced by 8.6% with the 4,134-share transaction.

Sloan Thomas H, who is SVP, Operations at Camden Property, sold 3,093 shares at $69.90 on Sept. 16, 2014. Following this transaction, the SVP, Operations owned 24,435 shares meaning that the stake was reduced by 11.24% with the 3,093-share transaction.

The shares most recently traded at $69.94, up $0.04, or 0.06% since the insider transaction. Historical insider transactions for Camden Property go as follows:

  • 4-Week # shares sold: 29,584
  • 12-Week # shares sold: 29,584
  • 24-Week # shares sold: 47,596

The average volume for Camden Property has been 413,500 shares per day over the past 30 days. Camden Property has a market cap of $6.0 billion and is part of the financial sector and real estate industry. Shares are up 22.77% year-to-date as of the close of trading on Tuesday.

Camden Property Trust is an independent real estate investment trust. The firm invests in the real estate markets of the United States. It is engaged in the ownership, development, acquisition, management, and disposition of multifamily residential apartment communities. The stock currently has a dividend yield of 3.79%. The company has a P/E ratio of 41.2. Currently, there are 7 analysts who rate Camden Property a buy, 1 analyst rates it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPT - FREE

TheStreet Quant Ratings rates Camden Property as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Camden Property Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PTC Therapeutics (PTCT) - FREE Research Report

Rothera Mark, who is Chief Commercial Officer at PTC Therapeutics, sold 8,000 shares at $36.24 on Sept. 16, 2014. Following this transaction, the Chief Commercial Officer owned 17,000 shares meaning that the stake was reduced by 32% with the 8,000-share transaction.

The shares most recently traded at $36.48, up $0.24, or 0.66% since the insider transaction. Historical insider transactions for PTC Therapeutics go as follows:

  • 4-Week # shares sold: 1,650
  • 12-Week # shares sold: 1,650
  • 24-Week # shares bought: 711,676
  • 24-Week # shares sold: 1,650

The average volume for PTC Therapeutics has been 285,500 shares per day over the past 30 days. PTC Therapeutics has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 113.38% year-to-date as of the close of trading on Tuesday.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. The company has a P/E ratio of 1.4. Currently, there are 5 analysts who rate PTC Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PTCT - FREE

TheStreet Quant Ratings rates PTC Therapeutics as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full PTC Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

LinkedIn (LNKD) - FREE Research Report

Sze David L, who is Director at LinkedIn, sold 1,500 shares at $213.94 on Sept. 16, 2014. Following this transaction, the Director owned 63,938 shares meaning that the stake was reduced by 2.29% with the 1,500-share transaction.

The shares most recently traded at $212.51, down $1.43, or 0.67% since the insider transaction. Historical insider transactions for LinkedIn go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 47,682
  • 24-Week # shares sold: 97,776

The average volume for LinkedIn has been 2.0 million shares per day over the past 30 days. LinkedIn has a market cap of $22.2 billion and is part of the technology sector and internet industry. Shares are down 2.05% year-to-date as of the close of trading on Tuesday.

LinkedIn Corporation operates an online professional network. Currently, there are 18 analysts who rate LinkedIn a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LNKD - FREE

TheStreet Quant Ratings rates LinkedIn as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full LinkedIn Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Global Stocks Retreat as U.S.-China Trade War Intensifies

Global Stocks Retreat as U.S.-China Trade War Intensifies

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods